Keyword: Herceptin

Novartis faces doctor kickback allegations in China, Samsung and AbbVie ink a Humira biosim settlement, and Takeda seeks financing for a Shire bid.

Thursday was a busy day for Europe’s regulators—and their whirl of activity will send several drugmakers into the weekend happy.

The biosimilar sales threat is getting real for Roche this year, but a lower tax rate means profits will grow just the same.

The risk of biosimilar competition to Roche's top cancer meds prompted one analyst to warn investors to “brace for impact.”

Analysts and investors think Perjeta’s end-of-the-year indication may not be as lucrative as they once hoped.

In other news of note, Bristol-Myers, Roche and Pfizer won new indications for key cancer drugs and Boehringer inked a marketing settlement.

Anyone hoping for an upheaval at the top of pharma's drug sales charts next year will have to keep waiting.

Takeda offloaded cancer assets, AstraZeneca formed drug discovery JV in China, Biocon's Herceptin biosimilar plant cleared FDA.

Mylan and Biocon today became the first drugmakers to win an FDA approval of a biosimilar of Roche's blockbuster cancer drug Herceptin.

Pfizer faces a legal hurdle to its proposed Herceptin biosimilar now that Roche has sued for patent infringement.